Eli Lilly's Christi Shaw bows out of top post at the Bio-Medicines unit
Less than 3 years after Eli Lilly CEO David Ricks recruited Novartis vet Christi Shaw to run their big Bio-Medicines business, she’s out.
In a statement put out Thursday morning, Lilly said that Shaw’s last day will come at the end of August. Patrik Jonsson, currently president and general manager of Lilly Japan, will succeed Shaw once he gets the paperwork sorted out.
Lilly’s shares dropped 4% on the news.
General counsel Mike Harrington is retiring at the end of the year.
A veteran pharma exec, Shaw had left a big job running Novartis’ US business to help care for her ailing sister. She talked about that a few months ago during our panel conversation on drug pricing and the relative value of new therapeutics, putting the issue in a human context.
If we want to take, like my sister, rare disease, multiple myeloma. Thank God we invested because she was on seven different medicines. She had a great quality of life for three out of four years, while she would’ve only gotten seven months before. Now, that may not mean a lot to everybody until it’s your own sister, until it’s your own patient, your own child, your mother.
During her tenure there, Shaw played a key role in launching new drug franchises like Emgality and Taltz, which factor into the company’s growth plans.
Her exit now at least temporarily eliminates one of the few women in a senior position at the world’s top 15 pharma giants.